Cargando…
Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
BACKGROUND: The intestinal uptake of the taxanes paclitaxel and docetaxel is seriously hampered by drug efflux through P-glycoprotein (P-gp) and drug metabolism via cytochrome P450 (CYP) 3A. The resulting low oral bioavailability can be boosted by co-administration of P-gp or CYP3A4 inhibitors. METH...
Autores principales: | Hendrikx, J J M A, Lagas, J S, Wagenaar, E, Rosing, H, Schellens, J H M, Beijnen, J H, Schinkel, A H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037831/ https://www.ncbi.nlm.nih.gov/pubmed/24781280 http://dx.doi.org/10.1038/bjc.2014.222 |
Ejemplares similares
-
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
por: Veltkamp, S A, et al.
Publicado: (2006) -
No relation between docetaxel administration route and high‐grade diarrhea incidence
por: Hendrikx, Jeroen J. M. A., et al.
Publicado: (2020) -
Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()
por: Sawicki, Emilia, et al.
Publicado: (2016) -
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022) -
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)